Bausch Health Companies Inc. (NASDAQ:BHC) | Finanzwire

Basculer en Français

8301	Companies
115073	Keywords
55420	Articles
62512	Press releases

Headlines Articles Press releases Bausch Health Companies Inc.

Home
Companies
Bausch Health Companies Inc.

BRIEF

published on 05/17/2024 at 14:05, 6 months 4 days ago

Salix Pharmaceuticals to Unveil Amiselimod Phase 2 Results at Digestive Disease Week 2024

Salix Pharmaceuticals Ulcerative Colitis Clinical Trial Digestive Disease Week Amiselimod
PRESS RELEASE

published on 05/17/2024 at 14:00, 6 months 4 days ago

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health & Salix Pharmaceuticals to present Phase 2 trial data on Amiselimod for ulcerative colitis treatment at DDW 2024. Positive results announced in 2023

Salix Pharmaceuticals Ulcerative Colitis Bausch Health DDW 2024 Amiselimod
BRIEF

published on 05/15/2024 at 14:05, 6 months 6 days ago

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Corporate Governance Bausch Health Shareholder Meeting Executive Compensation Omnibus Incentive Plan
PRESS RELEASE

published on 05/15/2024 at 14:00, 6 months 6 days ago

Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Bausch Health Companies Inc. announces results of 2024 annual meeting of shareholders, including election of directors and approval of executive compensation

Shareholders Bausch Health Companies Inc. Annual Meeting Directors Executive Compensation
BRIEF

published on 05/14/2024 at 22:26, 6 months 6 days ago

Bausch Health Announces Updates on Norwich XIFAXAN Litigation and New FDA Submission

XIFAXAN Bausch Health Patent Litigation FDA Submission Norwich Pharmaceuticals
PRESS RELEASE

published on 05/14/2024 at 22:21, 6 months 6 days ago

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Bausch Health and Salix Pharmaceuticals provide updates on litigation with Norwich Pharmaceuticals and potential generic version of XIFAXAN. Bausch Health to enforce intellectual property rights. Details on FDA approval process and patent infringement lawsuit

Salix Pharmaceuticals XIFAXAN Bausch Health Norwich Pharmaceuticals Intellectual Property Rights
BRIEF

published on 05/09/2024 at 14:05, 6 months 12 days ago

Salix Pharmaceuticals Appoints Bellamy Young as Spokesperson for Xifaxan Campaign

Salix Pharmaceuticals XIFAXAN FDA Approval Bellamy Young Overt Hepatic Encephalopathy
PRESS RELEASE

published on 05/09/2024 at 14:00, 6 months 12 days ago

Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Bausch Health and Salix Pharmaceuticals announce Bellamy Young as Xifaxan brand ambassador to raise awareness on OHE recurrence risk reduction. Campaign aims to educate about complications of cirrhosis

Salix Pharmaceuticals XIFAXAN Bausch Health Bellamy Young OHE Recurrence
BRIEF

published on 05/02/2024 at 13:05, 6 months 19 days ago

Bausch Health Announces First Quarter 2024 Results

Financial Results Adjusted EBITDA Pharmaceutical Industry Revenue Growth Bausch Health
PRESS RELEASE

published on 05/02/2024 at 13:00, 6 months 19 days ago

Bausch Health Announces First Quarter 2024 Results
Bausch Health Companies Inc. reports first quarter 2024 financial results with 11% revenue growth and continued year-over-year revenue increase in all segments. CEO Thomas J. Appio highlights focus on R&D pipeline, balance sheet strength, and global growth strategies

Financial Results Revenue Growth Bausch Health Companies Inc. CEO Thomas J. Appio R&D Pipeline

Accesswire

Published on 11/21/2024 at 17:35, 42 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 47 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 47 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 16 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 17 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 17:58, 18 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 25 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 26 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 16:00, 2 hours 17 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 2 hours 35 minutes ago

Edison issues report on Murray Income Trust (MUT)

Les Echos

Published on 11/21/2024 at 06:58, 11 hours 19 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 57 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 10 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE